NODia

Development of novel inhibitors of the nNOS-PIN complex for the treatment of type 2 diabetes.

Maturation project between the University of Montpellier and SATT AxLR

The nNOS and PIN proteins are both involved in controlling insulin secretion (Lajoix et al. Diabetes, 2001; 2004; 2006) and muscle sensitivity to glucose (Stamler et al., Physiol Rev, 2001) in rats and humans. In addition, molecular abnormalities of nNOS, particularly a reduction in its catalytic activity, are involved in pancreatic and muscle β-cell dysfunction in animal models of prediabetes (Mezghenna et al. Diabetologia, 2011; 2014).

Subtly inhibiting the interaction of nNOS with its inhibitor PIN is a way to restore normal nNOS catalytic activity and correct the pancreatic and muscular defects present in diabetes. This strategy therefore has major potential for the development of new antidiabetic treatments targeting people with recent-onset diabetes.

The objective of the project is to identify novel chemical molecules capable of modulating this molecular complex and exhibiting antidiabetic properties.